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Increasing evidence demonstrates a connection between growth factor function (includ-
ing brain-derived neurotrophic factor, BDNF), glucocorticoid levels (one of the steroid
hormones), and the pathophysiology of depressive disorders. Because both BDNF and
glucocorticoids regulate synaptic function in the central nervous system, their functional
interaction is of major concern. Interestingly, alterations in levels of estrogen, another
steroid hormone, may play a role in depressive-like behavior in postpartum females with
fluctuations of BDNF-related molecules in the brain. BDNF and cytokines, which are protein
regulators of inflammation, stimulate multiple intracellular signaling cascades involved in
neuropsychiatric illness. Pro-inflammatory cytokines may increase vulnerability to depres-
sive symptoms, such as the increased risk observed in patients with cancer and/or autoim-
mune diseases. In this review, we discuss the possible relationship between inflammation
and depression, in addition to the cross-talk among cytokines, BDNF, and steroids. Further,
since nutritional status has been shown to affect critical pathways involved in depression
through both BDNF function and the monoamine system, we also review current evidence
surrounding diet and supplementation (e.g., flavonoids) on BDNF-mediated brain functions.
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INTRODUCTION
In addition to genetic pre-dispositions, various environmental
factors are also well-established to contribute to the pathogen-
esis of depressive disorders. Specifically, prolonged exposures to
stressful environments, which result in chronic elevation of gluco-
corticoids, have been associated with depression onset (1). Gen-
erally, it is believed that glucocorticoid levels play several roles
in coping with stressful conditions. It is well-established that,
when receiving stressful stimuli, corticotropin-releasing hormone
(CRH) is released in the hypothalamus, which stimulates the ante-
rior pituitary to increase adrenocorticotropic hormone (ACTH)
levels. Subsequently, ACTH acts on the adrenal glands to upreg-
ulate the concentration of glucocorticoids for coping with stress.
However, one of the main causes of depression is hyperactiva-
tion of the hypothalamic–pituitary–adrenal axis (HPA axis) with
persistently increased levels of glucocorticoids. Ample evidence
demonstrates that glucocorticoid levels regulate neuronal trans-
mission and synaptic plasticity (2), though abnormally elevated
levels are recognized as a risk for depressive disorders (3). Thus,
chronic glucocorticoid exposure has been utilized as a reliable ani-
mal model of depression (4). Estrogen, another steroid, also plays
a role in neuronal plasticity, with altered levels proven to affect
mood. Remarkably, adolescent offspring from mothers suffering
from postpartum depression (PPD) exhibit higher susceptibility
to depression compared to those from healthy mothers (5). Lower
serum levels of estradiol were observed in women with major
depressive disorder (MDD) (6), and low-plasma concentrations
of estrogen were correlated with PPD (7). Although estrogen has
been considered as a major factor in the pathophysiology of PPD,
Wong et al. found that glucocorticoid levels also influence behav-
iors of mother rats and their subsequent pregnancy outcomes
including litter size and the proportion of male/female sex (8),
suggesting complex interactions among steroids in PPD. Further-
more,brain-derived neurotrophic factor (BDNF) plays an essential
role in neuronal plasticity, with the downregulation of BDNF
expression/function reproduced in a variety of animal models
of depression. Thus, in this review, we provide current knowl-
edge concerning dynamics of regulators for neuronal function
(glucocorticoid, estrogen, BDNF, etc.) in PPD.
When considering comorbid depression, the possible relation-
ship with pro-inflammatory cytokines is an important issue (9).
Meta-analytic studies have demonstrated the association of pro-
inflammatory cytokines such as tumor necrosis factor-α (TNF-
α) and interleukin-6 (IL-6) with MDD (10, 11). In rats, acute
intracerebroventricularly administration of IL-6 (50–200 ng) elic-
its depression-like behavior (12). It has been suggested that
patients suffering from cancers (in which the inflammatory sys-
tem is activated) have a higher prevalence of depressive symptoms
(13). Consistently, interferon-α (INF-α), which is used as a cancer
treatment, leads to depressive symptoms, suggesting involvement

























































Numakawa et al. BDNF dysfunction in comorbid depression
of cytokines in comorbid depression (14). Interestingly, nutri-
tional and metabolic disease such as diabetes and obesity may
also predispose individuals to depression (15). Oxidative insults,
dysfunction of the HPA axis, inflammation, and reduced BDNF-
related signaling have been identified as contributors to depression
in obesity (15, 16). Remarkably, biological functions, including
antioxidant (17), anti-cancer (18), and antidepressant-like effects
(19) of flavonoids (major component of polyphenols extracted
from plants) have been demonstrated. In the latter part of this
paper, we discuss the relationship between inflammation, obesity,
and overall brain function, introducing flavonoids as a potential
drug for improvement of important neural processes.
BASIC ROLES OF BDNF IN NEURONAL FUNCTION
The neurotrophin family consists of nerve growth factor (NGF),
BDNF, NT-3, and NT-4/5, which play a pivotal role in cell survival
and synaptic function in the peripheral and central nervous sys-
tems. Members of the neurotrophin family bind with high affinity
to their respective receptors, with NGF to TrkA, both BDNF and
NT-4/5 to TrkB and NT-3 to TrkC (1, 20). Research has explored
the interaction of neurotrophins with specific Trk receptors and
their stimulation of downstream signaling pathways including
phospholipase Cγ (PLCγ), phosphoinositide 3 kinase (PI3K)/Akt
and the extracellular signal-regulated kinase (ERK) pathways that
contribute to maintaining cell viability and regulation of synaptic
function, although common low-affinity receptor p75 has a neg-
ative role in cell survival (1, 20). Among the entire neurotrophin
family, BDNF/TrkB has been extensively examined regarding its
positive effects including neuroprotection against cell death induc-
tion and on the development of neural circuits (21, 22). The
Val66Met variation of BDNF is related with altered secretion of
BDNF protein that influences structural alterations of brain tis-
sue (23). In addition, it has been reported that genetic variant of
TrkB is also associated with the risk of depression (24–26), further
suggesting that the importance of BDNF/TrkB system in brain
function.
INFLUENCE OF ESTROGEN ON NEURONAL FUNCTION
In addition to BDNF, the contribution of estrogen to neural func-
tion is well-established. The major forms of estrogen consist of
estrone (E1), estradiol (E2, or 17β estradiol), and estriol (E3),
which are mainly produced in the ovaries, corpus luteum, and pla-
centa, through non-gonad organs such as liver and brain function
are slight producers (27). Hippocampal long-term potentiation
(LTP) is believed to be the basis of learning and memory. The
form of estrogen is important for learning and memory, given
that various doses of estrogen (E1, 17α estradiol, and E2) provide
enhancement or impairment in the contextual fear condition-
ing in ovariectomized rats (28). Using acute hippocampal slices
from ovariectomized rats, significant enhancement of LTP by 17β
estradiol was revealed (29). In this model, alteration of spine
density and N -methyl-d-aspartate (NMDA) glutamate receptor
function were involved (29). Furthermore, activation of RhoA
(small GTPase) and cofilin, as well as polymerization of actin,
are putatively involved in enhanced neurotransmission caused
by acute 17β estradiol application (30). In the learned helpless-
ness model using ovariectomized rats, loss of LTP and decreased
spine density in the hippocampus were observed in helpless ani-
mals compared with those of resilient animals (31). Importantly,
replacement of 17β estradiol increased hippocampal LTP and spine
density in both helpless and resilient rats (31).
Rodent studies have established a close relationship between
estrogen and BDNF in the regulation of neuronal function. It has
been demonstrated that 17β estradiol regulates mossy fiber neu-
rotransmission in the hippocampus, and that not only mature
BDNF/TrkB but also the precursor proBDNF/p75 system con-
tributes to estradiol-mediated hippocampal function (32). Inter-
estingly, in addition to classical nuclear receptors (ERα and ERβ),
the extranuclear receptor for estrogen also plays a role in estro-
gen function. Using ovariectomized female mice, Yang et al.
showed that E2 conjugates (binds to only extranuclear ER) pro-
tected neurons against global cerebral ischemia, and significantly
increased phosphorylation of cAMP response element-binding
protein (CREB) and BDNF expression via activation of ERK- and
Akt-pathways (33). Currently, ample evidence suggests that 17β
estradiol acutely affects synaptic plasticity via stimulating intra-
cellular signaling such as the ERK pathway in a similar fashion as
BDNF (34).
ESTROGEN AND POSTPARTUM DEPRESSION
Depression is a critical problem for postpartum women, because
PPD is thought to negatively influence both infant and mother.
Indeed, adolescent offspring of PPD mothers have approximately
five times greater risk of depression than offspring of healthy
mothers (5). It is known that symptoms of PPD appear in about
10% of postpartum mothers and that PPD increases rates of sui-
cide and consequent deaths (35). In addition, because infant care
by the mother during the perinatal period influences mental health
of offspring in adulthood (36), the possible mechanism underlying
the onset of PPD should be elucidated.
Generally, it has been recognized that a greater frequency of
women compared to men suffer from depressive disorders, with
the postpartum phase being a high-risk period. As expected, alter-
ations in estrogen-related genes and signaling are suspected to be
involved in PPD. A recent study found an association between
gene polymorphisms of estrogen receptor alpha and women with
PPD (37). With a genome-wide association study, it was con-
firmed that sensitivity to estrogen-related signaling is increased in
women with PDD (38). However, the association between estro-
gen levels and symptoms of PPD is still controversial. Mehta et al.
reported that no alteration in plasma estrogen concentration is
observed (38), whereas cross-species studies of PPD using rats
and humans show a possible contribution of reduced estrogen to
the pathogenesis of PPD (7). In addition to increased immobility
of estrogen-withdrawal rats in the forced swim test (FST), a cor-
relation between negative affect in 1-month postpartum women
with PPD episode and their daily estradiol concentrations has been
reported (7). Progesterone is highly produced sex hormone in the
luteal phase, and its withdrawal is also suggested to be involved
in PPD symptoms. Using the postpartum mouse model utilizing
progesterone withdrawal, it is revealed that acute combined appli-
cation of magnesium, zinc, and thiamine improve the depressive-
and anxiety-like behaviors (39). Furthermore, blockade of prog-
esterone receptor activity by the specific antagonist, CDB-4124,
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results in increased depressive-like behavior of female mice (40),
supporting the hypothesis of progesterone withdrawal in PPD
pathogenesis. Although detailed mechanism in the effect of some
nutrients on progesterone ability is still unknown, it is interesting
whether dietary supplementation attenuates the symptoms of PPD
through the regulation of sex hormones such as progesterone.
Very recently, it has been reported that postpartum rats after
chronic stress during their pregnant period exhibit depressive-like
behavior, impaired ability to care for their young, and decreased
spine density of pyramidal neurons in the medial prefrontal
cortex (41). Wong et al. examined the possible impact of corti-
costerone administration during the first postpartum period on
mother rats (8). Interestingly, increased depressive-like behavior
of dams in the first postpartum period was observed along with
a smaller litter size and less depressive-like behavior in the second
postpartum period (8). As stressful conditions during pregnancy
enhance the risk of depression, reduce maternal care, and neg-
atively affect offspring characteristics, detailed molecular mecha-
nisms behind PPD are desirable. Interestingly, Maniam and Morris
showed that postpartum mother rats after daily long-term separa-
tion from pups display depressive-like and anxiety-like behaviors
with increased plasma corticosterone, with high-fat diets (HFDs)
improving these behaviors and steroid levels (42). A neurochem-
ical approach using rats revealed that maternal isolation induces
reduced activity of Na+, K+-ATPase in the hippocampus of post-
partum mothers (43). Because the negative impact of maternal
isolation on postpartum mothers is not well understood com-
pared to offspring, increased PPD after maternal isolation is also
remarkable. Importantly, it has been suggested that changes in the
activity of Na+, K+-ATPase are involved in psychiatric diseases
including bipolar disorder (44, 45). Focusing on the specific mol-
ecular pathways related to each disease is very important in future
research. Although the influence of antidepressant treatment dur-
ing pregnancy is a critical concern, there are few animal models
for examination. Utilizing a rat model, Bourke et al. examined
the effect of exposure to escitalopram [a selective serotonin reup-
take inhibitor (SSRI)] during pregnancy, and found no substantial
change in maternal care. To prevent negative effects on the mental
and/or physical growth of offspring, further studies investigating
prenatal antidepressant treatment are important (46). SSRIs are
proven to be an effective treatment for PPD, though there is no
sufficient evidence to present clear superiority of SSRIs (47). A
recent randomized placebo-controlled, double-blind clinical trial
provided evidence that continued treatment of sertraline (SSRI)
attenuates early onset of PPD in women (48). Despite this, further
clinical tests are required to define the effectiveness of SSRIs for
PPD in compared to other antidepressants.
As expected, it has been demonstrated that serum BDNF levels
of women with postpartum affective disorders (depression, manic,
and mixed episode) showing suicide risk are lower than those of
women showing no risk (49). Interestingly, serum BDNF levels in
MDD subjects with longer disease duration is lower in woman,
whereas it is no association between serum BDNF and disease
duration in men (50). A study investigating a non-synonymous
single nucleotide polymorphism (SNP) of valine to methionine at
codon 66 (Val66Met) in the BDNF gene revealed a significant asso-
ciation between Met carriers and PPD development when focusing
on mothers whose delivery occurred during autumn/winter (51).
It has been also reported that serum BDNF levels in male homozy-
gous for Val and female Met carriers are higher than that in male
Met carriers and female homozygous of Val (52).
We have observed depressive-like behaviors in primiparous
female rats at 3 weeks postpartum compared with nulliparous rats
(53). Furthermore, decreased expression of ERα (not ERβ), and
increased expression of BDNF and its receptor TrkB in the medial
amygdala were observed at 3 weeks postpartum (53). Importantly,
administration of 17β estradiol and propyl pyrazole-triol (PPT,
selective ERα agonist) in primiparous mothers caused significant
upregulation of BDNF, TrkB, and pERK2 in the medial amygdala,
in addition to marked improvement of depressive-like behaviors
[Ref. (53), see Figure 1]. It is possible that amygdala ERα plays
a role in depressive-like behaviors, and that the BDNF/TrkB/ERK
system functions to recover from PPD, although further study
is required to reveal a relationship between function of ERα and
upregulation of BDNF in our model. Interestingly, ovariectomized
female rats treated by PPT exhibit anxiogenic behaviors in the
elevated plus-maze (EPM) test with increased corticosterone lev-
els, while activation of ERβ by diarylpropionitrile (DPN) reduces
anxiety-like behaviors and corticosterone levels (54). Although
estradiol has similar binding affinities to ERα and ERβ, subcuta-
neous injection of estradiol reduces depressive- and anxiety-like
behaviors (54). Further, intracerebral delivery of estradiol does
not alter anxiety-like behaviors in open field and EPM tests, but
increases active stress-coping behavior in the FST (55). Both ERα
and ERβ knockout mice are strong tools to investigate the contri-
bution of each estrogen receptor to brain function and molecular
regulation including BDNF-related signaling. In the hippocampus
of ovariectomized female mice, treatment with estradiol benzoate
increased activation of Akt and TrkB, whereas these estradiol
effects on Akt and TrkB are abolished in both ERα and ERβ
knockout mice (56). Remarkably, upregulation of BDNF mRNA
was induced by estradiol treatment in the hippocampus of ERα
knockout mice, while ERβ knockout mice showed no alteration in
the hippocampal BDNF expression after estradiol exposure, sug-
gesting involvement of ERβ in the regulation of BDNF expression
(56).
The lower estradiol and higher progesterone levels in serum
were observed in MDD women, which are associated with hypoac-
tivation in the hypothalamus, subgenual anterior cingulate cor-
tex, amygdala, and orbitofrontal cortex (6). A recent cohort
study demonstrated a significant inverse association between
follicle-stimulating hormone (FSH) and depressive symptoms in
women (age 35–47) (57). Estradiol treatment for 12 weeks in
postmenopausal women resulted in reduced FSH and luteiniz-
ing hormone, and increased dehydroepiandrosterone sulfate (58).
Furthermore, the treatment elicited a reduced response to CRH
on ACTH-release in the pituitary (58). Estrogen therapy is associ-
ated with improvement of PPD and potentiates the antidepressant
effect (by sertraline, 50 mg/day) on depressive symptoms in post-
menopausal women (59, 60). As these clinical reports suggest
that a possible association between estrogen and dysregulation
of the HPG- and HPA-axis in women with depression, the inter-
action among BDNF, estrogen, HPA axis, and HPG-axis is a critical
subject when considering treatment for PPD.
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FIGURE 1 | Possible involvement of ERα function and BDNF-related
signaling in PPD. We recently showed altered expression of ERα and
BDNF-related signaling in the rat amygdala [please see Ref. (53)].
(A) Experiment 1; four groups were made: control (diestrus nulliparous),
and 3-, 5-, or 10-weeks postpartum mother rats were produced. After
examining anxiety-like behavior [elevated plus-maze (EPM)] and
depression-like behaviors [forced swim test (FST)], immunostaining (for
both ERα and ERβ) and immunoblotting (for BDNF, TrkB, and pERK) were
performed. Further, to determine which estrogen receptor influences
depression-like behaviors most, E2, PPT (agonist for ERα), and DPN (for
ERβ) (please see Experiment 2) were applied to 3 week postpartum
mothers. Behavioral examination with EP and FS tests were carried out at
30 min after the fourth and sixth drug application, respectively. Brain
tissues (including amygdala) were also collected for immunochemical
analysis following behavioral examination. (B) We observed that 3 week
postpartum rats exhibited anxiety- and depression-like behaviors. This
PPD-like phenotype was associated with reduced ERα (not ERβ) in the
medial amygdala [please see Ref. (53)]. It was revealed that both E2 and
PPT canceled the PPD-like responses, suggesting that the importance of
ERα-mediated signaling. We speculated that the function of ERα is
important for the ERK pathway (possibly via the upregulation of
BDNF/TrkB) and that increased ERα/BDNF-related activity in the amygdala
plays a critical role in the neural restoration and compensation to recover
from PPD [please see Ref. (53)].
PSYCHIATRIC DISEASES, INFLAMMATION, AND CYTOKINES
Interestingly, certain signaling pathways downstream of
BDNF/TrkB are also activated by cytokines. However, in contrast
to purported antidepressant effect of BDNF signaling, cytokine
action is largely associated with depressive-like behaviors. The
cytokine network is incredibly complex with a plethora of cross-
talk between cytokines to regulate activation or inactivation of
immune systems (61). Several lines of evidence demonstrate an
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increase in levels of pro-inflammatory cytokines in the blood and
cerebrospinal fluid of patients suffering from psychiatric diseases
such as depression and schizophrenia (62–65). Epidemiological
studies have also proposed that such inflammation is one of the
major risk factors for depression and schizophrenia (66, 67). In a
clinical study, cytokine expression caused by lipopolysaccharides
(LPS) in monocytes obtained from healthy women was associ-
ated with depressive symptoms (68). Experimentally stimulating
the inflammatory response in animal models caused behavioral
deficits, which are reminiscent of psychiatric diseases.
Administration of LPS or pro-inflammatory cytokines [TNF-α,
interleukin-1β (IL-1β), etc.] in rodents acutely triggers a spec-
trum of behavioral deficits that are known as “sickness-behavior”
including diminished feeding, motor activity, and social behavior
(9, 69). In addition to sickness-behavior, inflammation induced
by LPS or cytokine administration facilitated development of
depressive-like behaviors (FST and tail suspension test), and
anhedonia (sucrose intake test), with recovery induced by anti-
depressant treatment (9, 70, 71). Interestingly, indoleamine 2,3-
dioxygenase (IDO), a tryptophan-catabolizing enzyme, has been
shown to mediate LPS- and complete Freund’s adjuvant-induced
depressive-like behavior (72, 73). IL-6 increases hippocampal
IDO expression levels with depressive-like behavior in FST (73),
suggesting that amino acid metabolism is possibly linked with
inflammation-induced comorbid depression.
Cytokine-mediated depressive-like behaviors remain a con-
troversial issue, as these behaviors are considered a rather non-
specific phenotype. It has been reported that intracerebroventric-
ular (i.c.v) injection of IL-1β caused both sickness- and depressive-
like behaviors along with increases in cortical IL-6 levels, whereas
IL-6 application achieved depressive-like behavior (not sickness)
but failed to change IL-1β levels (12). This implies that different
cytokines are involved in both depression and sickness behaviors,
and that IL-6 may contribute to the pathogenesis of depression,
though further studies are needed to reveal individual mechanisms
pertaining to each respective behavioral pattern.
Pro-inflammatory cytokines also induce activation of intra-
cellular signaling molecules including Janus kinases (JAK), c-jun
N-terminal kinase (JNK), p38, ERK, signal transducer and acti-
vator of transcription (STAT), and nuclear factor-κB (74, 75).
A variety of evidence shows that pro-inflammatory cytokines
affect the glucocorticoid receptor (GR) to ultimately influence the
HPA axis. An in vitro study using mouse fibroblast cells revealed
that IL-1 inhibited dexamethasone (an agonist for GR)-induced
translocation of cytoplasmic GR to the nucleus, and repressed
GR-mediated transcriptional activity (76–78). TNF-α also inhib-
ited gene transcription mediated by GR in HeLa cells through
stimulating p38 and JNK pathways (76, 79). Importantly, rats
receiving intraperitoneal administration of IL-1 showed increased
ACTH and corticosterone (rodent glucocorticoid) in blood due to
hypersecretion of CRH in hypothalamic neurons (80). This dys-
function of GR and hypersecretion of CRH after application of
pro-inflammatory cytokines might reflect hyperactivation of the
HPA axis as observed in depressed patients. In addition to the HPA
axis, expression/function of BDNF is also affected by cytokines.
For example, a single i.c.v injection of IL-1β upregulated both
BDNF and TrkB expression in mouse hippocampus, while daily
IL-1β administration (for 8 days) decreased both of these expres-
sion levels (81). Moreover, BDNF-stimulated signaling (Akt and
ERK, but not PLCγ) was reduced by IL-1β application in cortical
neurons (82). Tong et al. found that IL-1β application inhibited
facilitation of LTP by BDNF in rat hippocampal slice cultures via
suppressing IRS-1/Akt/CREB signaling (83). In their system, an
inhibitor for p38 signaling canceled the negative effect of IL-1β on
BDNF-mediated signal transduction and LTP, suggesting that p38
signaling plays an essential role in IL-1β function (83). Notably,
functional impairments of both GR and BDNF are achieved via
activating the identical p38 signaling cascade (78, 79, 83). Further
investigation addressing the possible contribution of p38 to the
pathogenesis of depressive disorders is needed.
PUTATIVE INVOLVEMENT OF CYTOKINES IN
CANCER-ASSOCIATED DEPRESSION
Multiple clinical studies have indicated a high-prevalence rate
of depression in patients with cancer (13). Since the discovery
that depressive symptoms correlate with shortened survival time
in cancer patients (84), the mechanism behind cancer-associated
depression has been a critical issue. In addition to the psycho-
logical stress of suffering from a life-threatening condition, the
physical decompensation caused by cancer itself and/or ther-
apy (including drug treatments) may play a role in comorbid
depression. For example, patients undergoing treatment of can-
cer with IFN-α (a pro-inflammatory cytokine) frequently exhibit
depressive symptoms, with cessation of cytokine therapy dimin-
ishing symptoms (14). A recent clinical trial demonstrated that
IFN-α therapy decreased serum levels of BDNF while increasing
depressive symptoms as rated by Montgomery–Asberg depres-
sion rating scale in hepatitis C patients (85). The effects of
IFN-α administration on behavior or plasma corticosterone lev-
els were relatively mild in rodents compared with that of IL-1β
or TNF-α (86). On the other hand, when mice are exposed to
psychosocial stressors, IFN-α administration induces a significant
increase in plasma cytokine levels (IL-6, -10, and TNF-α), plasma
corticosterone concentration and sickness-behavior, suggesting
that a synergistic effect of IFN-α with stressors on behavioral
and endocrine deficits (87). Remarkably, the direct secretion of
cytokines in tumor cells is also involved in cancer-related depres-
sive symptoms as development of depression may be linked to
elevated plasma IL-6 and ascites in patient with ovarian cancer
(88). Pyter et al. found that rats with mammary tumors caused
by N -nitroso-N -methylurea exhibited depressive- and anxiety-
like behaviors (but not sickness), and confirmed increased IL-
1β in tumor tissue and elevated levels of cytokines (IL-1β, -6,
-10, and TNF-α) in hippocampal regions (89). Lamkin et al.
also observed that ovarian carcinoma injected into female mice
elicited anhedonic, depressive-like behavior in addition to elevated
plasma IL-6, -10, and TNF-α concentrations. These phenomenon
caused by cancer transplantation were enhanced after exposure
to social isolation stress (90). These animal models are strong
tools to clarify the relationship between tumor and depressive-like
behaviors, however, detailed molecular and cellular level investiga-
tion concerning the impact of tumor-secreted cytokines on CNS
neurons is essential for understanding cancer-related comorbid
depression.
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While estrogen therapy is useful for depressive symptoms in
PPD (59, 60), tamoxifen, an antagonist for the ER, is used to treat
primary breast cancer with potentially deleterious effect on mood
(91). Further, some antidepressants (i.e., fluoxetine, paroxetine,
and sertraline) reduce the efficacy of tamoxifen via interaction
with cytochrome P450 2D6, an enzyme for tamoxifen metabo-
lism (92, 93), illustrating the challenges associated with treating a
patient with MDD and breast cancer.
The role of BDNF as a prognostic marker in breast cancer
has been postulated because increased BDNF expression has been
found in breast cancer tissue (94). Although low-BDNF expres-
sion levels decreased risk for tumor relapse more than high-BDNF
levels in breast cancer patients, the risk for early tumor relapse
increases from loss of BDNF (95). Because overexpression of
BDNF in breast cancer cells resulted in reduction of cell prolif-
eration, Huth et al. proposed a novel role of BDNF as a suppressor
of breast cancer (95). To establish a solid treatment method for
patients with comorbid disease, the basic mechanism including
the interaction between BDNF and estradiol in breast cancer is
worth further study.
BDNF IN OBESITY AND DEPRESSION
Metabolic syndrome including hypertension, hyperlipidemia, and
central obesity along with diabetes have been identified as risk
factors for psychiatric illnesses including depression and schizo-
phrenia (15, 96). A variety of factors including oxidative stress,
dysregulation of the HPA axis, imbalance of neurotransmitter
systems, inflammation, and neuroprogression including neurode-
generation and reduced neurogenesis, have been proposed to be
involved in the pathogenesis of obesity-related mental diseases
(15, 96). On the other hand, as BDNF contributes to the regula-
tion of both synaptic plasticity and energy metabolism including
feeding behavior (1, 97), the neurotrophin has been recognized
as a key target to clarify the relationship between metabolic and
psychiatric disease. The latter part of this review covers BDNF
and its effect on obesity and psychiatric disease in relation to diet.
Importantly, there are many reports and reviews concerning the
influence of nutrition, such as omega-3 fatty acids and amino
acids, on depression (98, 99). Here, we focus more on the bene-
ficial effects of flavonoids and zinc, as they have the potential to
activate the BDNF/TrkB system.
The Val66Met SNP in the BDNF gene has been shown to
cause significant dysfunction in dendritic trafficking and activity-
dependent secretion of BDNF, ultimately contributing to several
neurologic and psychiatric diseases (100). Concerning the rela-
tionship between the Val66Met SNP and obesity, an epidemiolog-
ical study in Korea demonstrated that the body mass index (BMI)
in the 66Met allele population is lower compared with that in
66Val (major allele), and that smoking moderated the increase
of BMI in both Val/Met and Met/Met genotypes (101). Fur-
ther, brain imaging and neuropsychological assessments showed
reduced cortical volume in obese people with the 66Met allele
compared with both healthy subjects and obese people with the
66Val allele (102). In addition, the allele 66Met obesity group
displayed significant perseveration on the Wisconsin card sort-
ing test, suggesting that the Met allele in obese populations is a
risk factor for dysfunction of the prefrontal cortex (102). Though
the detailed mechanisms involved in antipsychotic treatment and
development of obesity have not been elucidated, Zhang et al.
found that clozapine, an atypical antipsychotic for the treatment
of schizophrenia, potentiated the risk of metabolic syndrome
(103). A faster increase in glucose plasma levels in the Met/Met
genotype compared with that of the Val/Val or Val/Met geno-
types in male schizophrenic patients under chronic treatment of
clozapine (24 months) was observed, while other metabolic para-
meters (triglyceride and high-density cholesterol, etc.) showed
no significant difference among these genotypes (103). Impor-
tantly, this BDNF polymorphism is weakly associated with obesity,
though brain-specific conditional BDNF knockout mice exhibit
typical symptoms of obesity (hyperglycemia, hyperleptinemia,
high cholesterol, and hyperinsulinemia) due to abnormal appetite
regulation controlled by both neuropeptide Y (NPY) and pro-
opiomelanocortin (POMC) neurons in the hypothalamus (104).
Further, increased latency was observed in the light/dark explo-
ration test in BDNF deficient mice, indicating that the deletion of
brain BDNF induces both obesity and anxiety (104). It has been
reported that anorexigenic neurons in the ventromedial hypo-
thalamus regulate food intake via stimulation of thrombospondin
receptor α2δ1, and that the receptor is reduced in conditional
BDNF knockout mice (105). Overexpression of the α2δ1 recep-
tor by using the adenovirus gene transfer system partially reversed
increased food intake and improved metabolic status such as glu-
cose intolerance in BDNF deficient mice (105). BDNF may have a
protective role against the progression of obesity.
Opposite to energy intake, energy expenditure (by exercise, etc.)
is considered to improve brain function. In the obese population,
decreased expression levels of neurotrophins (NGF and BDNF)
and associated receptors (TrkA and TrkB, respectively) elicited
by a HFD were observed, through attenuation of neurotrophin
downregulation was achieved by training and/or consuming a
normal calorie diet (106). A possible mechanism behind exercise-
dependent BDNF induction has been demonstrated. Wrann et al.
found that exercise upregulated hippocampal BDNF through
stimulating peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α), which contributes to mitochon-
drial biogenesis and oxidative metabolism (107). Knockdown of
fibronectin type III domain-containing protein 5 (FNDC5), a
target gene of PGC-1α, diminished BDNF expression without
any influence on other growth factors (CNTF, GDNF, NGF, and
IGF-1), suggesting that BDNF plays a role in energy metabolism
via the PGC-1α/FNDC5-mediated pathway (107). These reports
corroborate the notion that exercise is a beneficial intervention
promoting a healthy physical and mental state.
ALTERED SYNAPTIC PLASTICITY IN OBESITY AND POSSIBLE
INFLUENCE OF HPA AXIS
Recently, impairment of BDNF-related intracellular signaling in
metabolic diseases has been demonstrated. In addition to expres-
sion of hippocampal BDNF, its receptor TrkB was decreased in
leptin deficient mice exhibiting obesity, while levels of NT-3 were
intact (16). Hyperglycemia and downregulation of both BDNF
and TrkB in leptin deficient mice were recovered by adrenalec-
tomy or low-dose corticosterone replacement (16), suggesting that
glycemic status affects the BDNF/TrkB system through the HPA
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axis. Consistently, Wosiski-Kuhn et al. found that acute decrease
of corticosterone by treatment with metyrapone, an inhibitor for
corticosterone synthesis, improved deficits in hippocampal expres-
sion of BDNF and TrkB in leptin deficient mice (108). They
also confirmed reduced hippocampal BDNF and excitatory post-
synaptic potential slope after intrahippocampal corticosterone
injection (108), implying that chronic GR activation in the hip-
pocampal region impairs synaptic plasticity through repressing
the BDNF/TrkB system in metabolic diseases.
Recent research suggests that a HFD can lead to an imbalance
of glutamate metabolism in brain tissue (109). A HFD (45 kcal%
fat, 35 kcal% carbohydrates, and 20 kcal% protein, for 8 weeks)
caused an increase in glutamate uptake efficiency in the hippocam-
pus due to upregulation of glutamate transporters (GLT-1 and
GLAST), and impairs hippocampal synaptic plasticity including
both basal and NMDA-mediated long-term depression (109). In
other research, impaired memory function (novel object recog-
nition) and behavioral flexibility after 8-weeks consumption of a
HFD (38 kcal% fat and 38 kcal% refined sugar) were shown (110).
Proteomic analysis has also revealed that a HFD affected levels of
various proteins in the dorsal and ventral hippocampal regions,
including calcium/calmodulin-dependent protein kinase type II
(CaMKII) subunit delta and glutamate receptor 3 (GluR3) (110),
both involved in hippocampal synaptic plasticity. Importantly, a
high-fat sucrose diet (39 kcal% fat and 40 kcal% sucrose) aggra-
vates traumatic brain injury by fluid percussion with reduction
of hippocampal BDNF expression (111). Furthermore, reduction
of BDNF in the hippocampus and cortex is also involved in HFD
(60 kcal% fat)-caused depressive- and anxiety-like behaviors (112,
113). Of note, full-length and truncated types of TrkB (recep-
tor for BDNF) are not downregulated by HFD (113). Although
the relationship between obesity and regulators of synaptic func-
tion including BDNF remain to be elucidated, current research is
underway.
ACTION OF FLAVONOIDS, NATURAL COMPOUNDS, ON
BRAIN FUNCTION
Flavonoids are rich in plants and vegetables, and their beneficial
functions as cancer-preventing (18) and antioxidant agents (17)
have been proposed. For example, quercetin, a typical flavonoid,
rescues neuronal cells against oxidative stress induced by H2O2
exposure through the reduction of reactive oxygen species (114).
Nuclear factor E2-related factor 2 (Nrf2)/antioxidant response
element (ARE) is critical for the protective action of flavonoids
under oxidative insult and is expected to be the potential target
for improvement of neurodegeneration (115, 116). Using ani-
mal behavioral analysis, studies have shown the antidepressant
effect of flavonoids. A significant increase in social interaction
time and decreased immobility time in the FST after oral adminis-
tration of quercetin (20–40 mg/kg) was observed in rats, matching
the efficacy of the antidepressant fluoxetine (117). Interestingly,
quercetin also attenuates both corticotrophin releasing factor-
caused depressive-like behavior and water immersion-restraint
stress-induced release of corticosterone (117, 118), strongly sug-
gesting influence on the HPA axis.
Current evidence indicates that flavonoids activate intracellular
signaling. Using cultured cortical neurons from rats, we recently
observed that flavonoids obtained from the plant Iris tenuifolia
prevent cell death induction by oxidative insult via stimulating
phosphorylation of Src homology-2 (SH2) domain-containing
phosphatase 2 (Shp2) [Ref. (119), see Figure 2]. Remarkably, Jang
et al. found that 7,8-dihydroxyflavone (7,8-DHF), which has been
recognized as a new TrkB agonist after screening of various types
of flavonoids, exerts potent protective effects equivalent to that
of BDNF on hippocampal and cortical neurons (120). In another
report, the antioxidant function of 7,8-DHF was also confirmed
under oxidative stress caused by H2O2 exposure (121). Inter-
estingly, studies using conditional TrkB (Single neuron labeling
In Cre-mediated knockout :trkB) or BDNF (tamoxifen-Cre:BDNF)
FIGURE 2 | Flavonoids and zinc exert multiple beneficial effects on CNS
neurons. Flavonoids play multiple roles in the CNS, including promoting
antioxidant effects and stimulating intracellular signaling. Further, recent
evidence suggests that flavonoids act as TrkB receptor agonists, facilitating
neuroprotection and antidepressant effects. The utility of zinc, including
modulation of synapses, stimulation of TrkB, maintaining BDNF expression,
and exerting antidepressant effects, is also shown. The molecular
mechanisms behind the beneficial effects of these nutrients may be a
potential target to improve depression in PPD, inflammation, and metabolic
diseases.
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knockout mice have consistently demonstrated flavonoid efficacy
(122). English et al. found that administration of 7,8-DHF in fib-
rin glue promoted axon regeneration in wild-type, but not in TrkB
knockout mice. On the other hand, BDNF knockout mice receiv-
ing the same treatment showed increased axon length, suggesting
that 7,8-DHF has a positive effect on axon profiles via stimulating
TrkB even in the absence of BDNF (122). Furthermore, daily injec-
tion of 7,8-DHF (intraperitoneal; i.p., 5 mg/kg) induced phospho-
rylation of TrkB in the hippocampus and improved anhedonia-
(sucrose preference test) and depressive-like-behaviors (open-field
test) caused by chronic alcohol consumption (19). In limited
to the Huntington’s disease mouse model, activation of TrkB
leads to significant improvement of motor function, brain atro-
phy, and survival after treatment with 7,8-DHF (p.o., 5 mg/kg)
or by 4′-dimethylamino-7,8-DHF (a derivative of 7,8-DHF., p.o.,
1 mg/kg) (123).
ACTION OF ZINC IN DEPRESSION
Zinc, one of the essential minerals, has been extensively studied in
animal models of depression, demonstrating robust antidepres-
sant properties (124). Szewczyk et al. demonstrated that zinc defi-
ciency increases risk of depression and Alzheimer’s disease, while
supplementation of zinc is an effective treatment of these disorders
(125). Consistently, zinc deficiencies were observed in 41.0% of
psychogeriatric patients including depressive disorders, compared
to 14.4% of the control group demonstrating this deficiency (126).
Intracellular Zn2+ concentration is maintained through activ-
ity of zinc transporters consisting of Slc30a (ZnT1-10; exporting
cytosol Zn2+ to organelles or outside of the cells) and Slc39 (ZIP1-
14; passing Zn2+ into cytosol) families (127, 128), each affecting
synaptic function of glutamatergic neurons (129–131). In hip-
pocampal mossy fibers, the zinc transporter-3 (ZnT-3) plays a
role in recycling zinc to stimulate ERK via inhibiting tyrosine
phosphatase activity, resulting in positive regulation of mem-
ory function (129). In dendritic spines of hippocampal neurons,
zinc transporter-1 (ZnT-1) has also been found to contribute to
synaptic zinc homeostasis (130). Zrt/Irt-like protein 12 (ZIP12)
stimulates CREB and promotes neurite outgrowth (131). Inter-
estingly, G-protein coupled receptor 39 (GPR39; recognized as a
zinc receptor) is expressed in neuronal cells (132). Synaptic zinc
evokes synthesis of endocannabinoid 2-arachidonoylglycerol (2-
AG) through stimulating GPR39, leading to decreased presynaptic
neurotransmitter release (133). Furthermore, zinc also functions
as an agonist for TrkB and potentiates LTP of CA3 synapses in
hippocampal mossy fibers (134). Concerning cell survival, it has
been reported that increased apoptotic cell death in hippocampal
regions (including CA1, CA3, and dentate gyrus) and decreased
phosphorylation of hippocampal TrkB and ERK were observed
in lactating zinc deficient (0.85 ppm) mice (135). Importantly,
a zinc deficient diet (0.2 and 1 ppm) for 3 and 6 weeks caused
depressive and anxiety-like behaviors in addition to anhedonia
(136–138), while these depressive-like behaviors were reversed
after chronic treatment with typical antidepressants (such as flu-
oxetine, imipramine, and reboxetine) (136, 138). In addition, such
zinc deficiency in the diet induced downregulation of GPR39,
BDNF, and its receptor TrkB in both hippocampal and cortical
regions when compared with adequate zinc (33.5 ppm) (138). All
FIGURE 3 | Possible role of BDNF in comorbid depression. It is possible
that BDNF system is impaired in comorbid depression in postpartum,
inflammatory conditions including cancers, and metabolic disease through
the change of various factors (estradiol, HPA axis, cytokines, and energy
intake). As BDNF regulates a variety of brain functions, further investigation
on BDNF dysfunction in each condition such as postpartum, cancers, and
obesity may contribute to clarify the complex mechanism in comorbid
depression.
these studies suggest that the possibility of zinc homeostasis is
associated with mood status and BDNF-related neuronal function.
CONCLUSION
It has been suggested that both BDNF and glucocorticoid regu-
lation are potential targets of therapy for major depression. In
this paper, the molecular dynamics including downregulation of
BDNF in brain tissues and altered activity of the HPA axis in PPD,
inflammatory conditions, and metabolic disease are discussed
(see Figure 3). Investigation concerning the intricate relation-
ship between major factors (estrogen, glucocorticoids, cytokines,
BDNF, etc.) and their specific role in the development of depres-
sion is critical. Basic analysis using gene-deficient/overexpression
mice combined with exposure to other factors may be attrac-
tive. For example, further examination of cytokine administra-
tion using brain-specific GR- or BDNF-deficient mice may reveal
detailed linkage among glucocorticoids, BDNF, and inflammation.
As shown in the latter part of the paper, current studies demon-
strate the beneficial effects of flavonoids and zinc, both acting as
TrkB agonists. While several reports demonstrate the protective
effects of flavonoids and zinc against metabolic disease (139, 140),
effects of these nutrients on depression in PPD or inflammation-
related diseases remains to be elucidated. To truly understand
comorbid depression due to inflammation and metabolic disease,
more detailed investigation of peripheral metabolism and brain
function is needed.
ACKNOWLEDGMENTS
This study was supported by the Health and Labor Sciences
Research Grants (Comprehensive Research on Disability, Health,
and Welfare H21-kokoro-002) (Hiroshi Kunugi), Intramural
Research Grant (No. 24-11) for Neurological and Psychiatric
Disorders of NCNP (Hiroshi Kunugi), and Takeda Science Foun-
dation (Tadahiro Numakawa). This is also supported by a grant
from the Grant-in-Aid for Scientific Research (B) (JSPS KAK-
ENHI Grant Number 24300139) (Tadahiro Numakawa) and

























































Numakawa et al. BDNF dysfunction in comorbid depression
for Challenging Exploratory Research (JSPS KAKENHI Grant
Number 25640019) (Tadahiro Numakawa) from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan.
REFERENCES
1. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H. Brain-derived
neurotrophic factor and glucocorticoids: reciprocal influence on the central
nervous system. Neuroscience (2013) 239:157–72. doi:10.1016/j.neuroscience.
2012.09.073
2. Myers B, McKlveen JM, Herman JP. Glucocorticoid actions on synapses, cir-
cuits, and behavior: implications for the energetics of stress. Front Neuroen-
docrinol (2014) 35:180–96. doi:10.1016/j.yfrne.2013.12.003
3. Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med
(2013) 43:449–69. doi:10.1017/S0033291712000955
4. Sterner EY, Kalynchuk LE. Behavioral and neurobiological consequences of
prolonged glucocorticoid exposure in rats: relevance to depression. Prog Neu-
ropsychopharmacol Biol Psychiatry (2010) 34:777–90. doi:10.1016/j.pnpbp.
2010.03.005
5. Pawlby S,Hay DF,Sharp D,Waters CS,O’KeaneV. Antenatal depression predicts
depression in adolescent offspring: prospective longitudinal community-based
study. J Affect Disord (2009) 113:236–43. doi:10.1016/j.jad.2008.05.018
6. Holsen LM, Spaeth SB, Lee JH, Ogden LA, Klibanski A, Whitfield-Gabrieli S,
et al. Stress response circuitry hypoactivation related to hormonal dysfunc-
tion in women with major depression. J Affect Disord (2011) 131:379–87.
doi:10.1016/j.jad.2010.11.024
7. Schiller CE, O’Hara MW, Rubinow DR, Johnson AK. Estradiol modulates anhe-
donia and behavioral despair in rats and negative affect in a subgroup of women
at high risk for postpartum depression. Physiol Behav (2013) 119:137–44.
doi:10.1016/j.physbeh.2013.06.009
8. Wong JH, Brummelte S, Galea LA. Elevated corticosterone levels during the
first postpartum period influence subsequent pregnancy outcomes and behav-
iours of the dam. J Neuroendocrinol (2011) 23:1156–65. doi:10.1111/j.1365-
2826.2011.02169.x
9. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflam-
mation to sickness and depression: when the immune system subjugates the
brain. Nat Rev Neurosci (2008) 9:46–56. doi:10.1038/nrn2297
10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-
analysis of cytokines in major depression. Biol Psychiatry (2010) 67:446–57.
doi:10.1016/j.biopsych.2009.09.033
11. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-
α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with
major depressive disorder: a meta-analysis and meta-regression. J Affect Disord
(2012) 139:230–9. doi:10.1016/j.jad.2011.08.003
12. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss
SJ, et al. Evidence for sustained elevation of IL-6 in the CNS as a key
contributor of depressive-like phenotypes. Transl Psychiatry (2012) 2:e199.
doi:10.1038/tp.2012.120
13. Raison CL, Miller AH. Depression in cancer: new developments regarding
diagnosis and treatment. Biol Psychiatry (2003) 54:283–94. doi:10.1016/S0006-
3223(03)00413-X
14. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced
depression. J Affect Disord (2004) 82:175–90. doi:10.1016/j.jad.2004.04.002
15. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities
in dysregulated biological pathways and their implications for treatment. Prog
Neuropsychopharmacol Biol Psychiatry (2013) 45:92–9. doi:10.1016/j.pnpbp.
2013.05.005
16. Stranahan AM, Arumugam TV, Mattson MP. Lowering corticosterone levels
reinstates hippocampal brain-derived neurotropic factor and Trkb expression
without influencing deficits in hypothalamic brain-derived neurotropic fac-
tor expression in leptin receptor-deficient mice. Neuroendocrinology (2011)
93:58–64. doi:10.1159/000322808
17. Duthie G, Morrice P. Antioxidant capacity of flavonoids in hepatic microsomes
is not reflected by antioxidant effects in vivo. Oxid Med Cell Longev (2012)
2012:165127. doi:10.1155/2012/165127
18. González-Vallinas M, González-Castejón M, Rodríguez-Casado A, Ramírez de
Molina A. Dietary phytochemicals in cancer prevention and therapy: a comple-
mentary approach with promising perspectives. Nutr Rev (2013) 71:585–99.
doi:10.1111/nure.12051
19. Briones TL, Woods J. Chronic binge-like alcohol consumption in adolescence
causes depression-like symptoms possibly mediated by the effects of BDNF
on neurogenesis. Neuroscience (2013) 254:324–34. doi:10.1016/j.neuroscience.
2013.09.031
20. Ichim G, Tauszig-Delamasure S, Mehlen P. Neurotrophins and cell death. Exp
Cell Res (2012) 318:1221–8. doi:10.1016/j.yexcr.2012.03.006
21. Fargali S, Sadahiro M, Jiang C, Frick AL, Indall T, Cogliani V, et al. Role of
neurotrophins in the development and function of neural circuits that regu-
late energy homeostasis. J Mol Neurosci (2012) 48:654–9. doi:10.1007/s12031-
012-9790-9
22. Chen A, Xiong LJ, Tong Y, Mao M. The neuroprotective roles of BDNF in
hypoxic ischemic brain injury. Biomed Rep (2013) 1:167–76.
23. Chaieb L, Antal A, Ambrus GG, Paulus W. Brain-derived neurotrophic factor:
its impact upon neuroplasticity and neuroplasticity inducing transcranial brain
stimulation protocols. Neurogenetics (2014) 15:1–11. doi:10.1007/s10048-014-
0393-1
24. Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, Menke A, et al.
Association of genetic variants in the neurotrophic receptor-encoding gene
NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch
Gen Psychiatry (2010) 67:348–59. doi:10.1001/archgenpsychiatry.2009.201
25. Murphy ML, Carballedo A, Fagan AJ, Morris D, Fahey C, Meaney J, et al. Neu-
rotrophic tyrosine kinase polymorphism impacts white matter connections
in patients with major depressive disorder. Biol Psychiatry (2012) 72:663–70.
doi:10.1016/j.biopsych.2012.04.015
26. Li Z, Zhang Y, Wang Z, Chen J, Fan J, Guan Y, et al. The role of BDNF, NTRK2
gene and their interaction in development of treatment-resistant depression:
data from multicenter, prospective, longitudinal clinic practice. J Psychiatr Res
(2013) 47:8–14. doi:10.1016/j.jpsychires.2012.10.003
27. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging:
from periphery to brain. Trends Mol Med (2013) 19:197–209. doi:10.1016/j.
molmed.2012.12.007
28. Barha CK, Dalton GL, Galea LA. Low doses of 17alpha-estradiol and 17beta-
estradiol facilitate, whereas higher doses of estrone and 17alpha- and 17beta-
estradiol impair, contextual fear conditioning in adult female rats. Neuropsy-
chopharmacology (2010) 35:547–59. doi:10.1038/npp.2009.161
29. Smith CC, Vedder LC, McMahon LL. Estradiol and the relationship between
dendritic spines, NR2B containing NMDA receptors, and the magnitude of
long-term potentiation at hippocampal CA3-CA1 synapses. Psychoneuroen-
docrinology (2009) 34(Suppl 1):S130–42. doi:10.1016/j.psyneuen.2009.06.003
30. Babayan AH, Kramár EA. Rapid effects of oestrogen on synaptic plasticity:
interactions with actin and its signalling proteins. J Neuroendocrinol (2013)
25:1163–72. doi:10.1111/jne.12108
31. Bredemann TM, McMahon LL. 17β Estradiol increases resilience and improves
hippocampal synaptic function in helpless ovariectomized rats. Psychoneuroen-
docrinology (2014) 42:77–88. doi:10.1016/j.psyneuen.2014.01.004
32. Harte-Hargrove LC, Maclusky NJ, Scharfman HE. Brain-derived neurotrophic
factor-estrogen interactions in the hippocampal mossy fiber pathway: impli-
cations for normal brain function and disease. Neuroscience (2013) 239:46–66.
doi:10.1016/j.neuroscience.2012.12.029
33. Yang LC, Zhang QG, Zhou CF, Yang F, Zhang YD, Wang RM, et al. Extranuclear
estrogen receptors mediate the neuroprotective effects of estrogen in the rat
hippocampus. PLoS One (2010) 5:e9851. doi:10.1371/journal.pone.0009851
34. Srivastava DP, Woolfrey KM, Evans PD. Mechanisms underlying the interac-
tions between rapid estrogenic and BDNF control of synaptic connectivity.
Neuroscience (2013) 239:17–33. doi:10.1016/j.neuroscience.2012.12.004
35. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy
and the postpartum. Arch Womens Ment Health (2005) 8:77–87. doi:10.1007/
s00737-005-0080-1
36. Tarantino LM, Sullivan PF, Meltzer-Brody S. Using animal models to disentan-
gle the role of genetic, epigenetic, and environmental influences on behavioral
outcomes associated with maternal anxiety and depression. Front Psychiatry
(2011) 2:44. doi:10.3389/fpsyt.2011.00044
37. Pinsonneault JK, Sullivan D, Sadee W, Soares CN, Hampson E, Steiner
M. Association study of the estrogen receptor gene ESR1 with postpartum
depression – a pilot study. Arch Womens Ment Health (2013) 16:499–509.
doi:10.1007/s00737-013-0373-8
38. Mehta D, Newport DJ, Frishman G, Kraus L, Rex-Haffner M, Ritchie JC, et al.
Early predictive biomarkers for postpartum depression point to a role for
estrogen receptor signaling. Psychol Med (2014) 5:1–14.

























































Numakawa et al. BDNF dysfunction in comorbid depression
39. Nikseresht S, Etebary S, Karimian M, Nabavizadeh F, Zarrindast MR,
Sadeghipour HR. Acute administration of Zn, Mg, and thiamine
improves postpartum depression conditions in mice. Arch Iran Med (2012)
15:306–11.
40. Beckley EH, Scibelli AC, Finn DA. Progesterone receptor antagonist CDB-4124
increases depression-like behavior in mice without affecting locomotor abil-
ity. Psychoneuroendocrinology (2011) 36:824–33. doi:10.1016/j.psyneuen.2010.
11.004
41. Leuner B, Fredericks PJ, Nealer C, Albin-Brooks C. Chronic gestational stress
leads to depressive-like behavior and compromises medial prefrontal cor-
tex structure and function during the postpartum period. PLoS One (2014)
9:e89912. doi:10.1371/journal.pone.0089912
42. Maniam J, Morris MJ. Long-term postpartum anxiety and depression-like
behavior in mother rats subjected to maternal separation are ameliorated by
palatable high fat diet. Behav Brain Res (2010) 208:72–9. doi:10.1016/j.bbr.
2009.11.005
43. von Poser Toigo E, Diehl LA, Ferreira AG, Mackedanz V, Krolow R, Benitz AN,
et al. Maternal depression model: long-lasting effects on the mother following
separation from pups. Neurochem Res (2012) 37:126–33. doi:10.1007/s11064-
011-0590-3
44. Kirshenbaum GS, Burgess CR, Déry N, Fahnestock M, Peever JH, Roder JC.
Attenuation of mania-like behavior in Na(+),K(+)-ATPase α3 mutant mice by
prospective therapies for bipolar disorder: melatonin and exercise. Neuroscience
(2014) 260:195–204. doi:10.1016/j.neuroscience.2013.12.011
45. el-Mallakh RS, Wyatt RJ. The Na K-ATPase hypothesis for bipolar illness. Biol
Psychiatry (1995) 37:235–44. doi:10.1016/0006-3223(94)00201-D
46. Bourke CH, Capello CF, Rogers SM, Yu ML, Boss-Williams KA, Weiss JM, et al.
Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model
of maternal depression and its treatment. Psychopharmacology (Berl) (2013)
228:231–41. doi:10.1007/s00213-013-3030-z
47. De Crescenzo F, Perelli F, Armando M, Vicari S. Selective serotonin reup-
take inhibitors (SSRIs) for post-partum depression (PPD): a systematic
review of randomized clinical trials. J Affect Disord (2014) 15(2–154):39–44.
doi:10.1016/j.jad.2013.09.019
48. Hantsoo L, Ward-O’Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epper-
son CN. A randomized, placebo-controlled, double-blind trial of sertraline
for postpartum depression. Psychopharmacology (Berl) (2014) 231:939–48.
doi:10.1007/s00213-013-3316-1
49. Pinheiro RT, Pinheiro KA, da Cunha Coelho FM, de Ávila Quevedo L, Gazal M,
da Silva RA, et al. Brain-derived neurotrophic factor levels in women with post-
partum affective disorder and suicidality. Neurochem Res (2012) 37:2229–34.
doi:10.1007/s11064-012-0851-9
50. de Azevedo Cardoso T, Mondin TC, Wiener CD, Marques MB, Fucolo Bde
Á, Pinheiro RT, et al. Neurotrophic factors, clinical features and gender dif-
ferences in depression. Neurochem Res (2014) 39:1571–8. doi:10.1007/s11064-
014-1349-4
51. Comasco E, Sylven SM, Papadopoulos FC, Oreland L, Sundstrom-Poromaa I,
Skalkidou A. Postpartum depressive symptoms and the BDNF Val66Met func-
tional polymorphism: effect of season of delivery. Arch Womens Ment Health
(2011) 14:453–63. doi:10.1007/s00737-011-0239-x
52. Elfving B, Buttenschøn HN, Foldager L, Poulsen PH, Andersen JH, Gryn-
derup MB, et al. Depression, the Val66Met polymorphism, age, and gen-
der influence the serum BDNF level. J Psychiatr Res (2012) 46:1118–25.
doi:10.1016/j.jpsychires.2012.05.003
53. Furuta M, Numakawa T, Chiba S, Ninomiya M, Kajiyama Y, Adachi N, et al.
Estrogen, predominantly via estrogen receptor α, attenuates postpartum-
induced anxiety- and depression-like behaviors in female rats. Endocrinology
(2013) 154:3807–16. doi:10.1210/en.2012-2136
54. Lund TD, Rovis T, Chung WC, Handa RJ. Novel actions of estrogen receptor-
beta on anxiety-related behaviors. Endocrinology (2005) 146:797–807. doi:10.
1210/en.2004-1158
55. Donner N, Handa RJ. Estrogen receptor beta regulates the expression of
tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dor-
sal raphe nuclei. Neuroscience (2009) 163:705–18. doi:10.1016/j.neuroscience.
2009.06.046
56. Spencer-Segal JL, Tsuda MC, Mattei L, Waters EM, Romeo RD, Milner TA, et al.
Estradiol acts via estrogen receptors alpha and beta on pathways important for
synaptic plasticity in the mouse hippocampal formation. Neuroscience (2012)
202:131–46. doi:10.1016/j.neuroscience.2011.11.035
57. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L.
Hormones and menopausal status as predictors of depression in women in
transition to menopause. Arch Gen Psychiatry (2004) 61:62–70. doi:10.1001/
archpsyc.61.1.62
58. Cucinelli F, Soranna L, Barini A, Perri C, Leoni F, Mancuso S, et al. Estrogen
treatment and body fat distribution are involved in corticotropin and corti-
sol response to corticotropin-releasing hormone in postmenopausal women.
Metabolism (2002) 51:137–43. doi:10.1053/meta.2002.29971
59. Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for prevent-
ing and treating postpartum depression. Cochrane Database Syst Rev (2008)
CD001690. doi:10.1002/14651858.CD001690.pub2
60. Rasgon NL, Dunkin J, Fairbanks L, Altshuler LL, Troung C, Elman S, et al.
Estrogen and response to sertraline in postmenopausal women with major
depressive disorder: a pilot study. J Psychiatr Res (2007) 41:338–43. doi:10.
1016/j.jpsychires.2006.03.009
61. Seillet C, Belz GT, Mielke LA. Complexity of cytokine network regulation
of innate lymphoid cells in protective immunity. Cytokine (2014) 70:1–10.
doi:10.1016/j.cyto.2014.06.002
62. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Biol Psychiatry (2011) 70:663–71. doi:10.1016/j.biopsych.2011.04.013
63. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al.
Increased cerebrospinal fluid interleukin-6 levels in patients with schizophre-
nia and those with major depressive disorder. J Psychiatr Res (2013) 47:401–6.
doi:10.1016/j.jpsychires.2012.12.001
64. Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The
plasma levels of various cytokines are increased during ongoing depression and
are reduced to normal levels after recovery. Psychoneuroendocrinology (2014)
45:77–86. doi:10.1016/j.psyneuen.2014.03.019
65. Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and
“resiliency” proteins in the CSF of patients with major depression. Depress
Anxiety (2012) 29:32–8. doi:10.1002/da.20876
66. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neu-
rocognitive alterations in the course of schizophrenia. Biol Psychiatry (2013)
73:951–66. doi:10.1016/j.biopsych.2013.01.001
67. Halaris A. Inflammation, heart disease, and depression. Curr Psychiatry Rep
(2013) 15:400. doi:10.1007/s11920-013-0400-5
68. Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of
cytokines and chemokines by blood monocytes to in vitro lipopolysac-
charide stimulation are associated with hostility and severity of depressive
symptoms in healthy women. Psychoneuroendocrinology (2004) 29:1119–28.
doi:10.1016/j.psyneuen.2004.01.002
69. Bluthé RM, Layé S, Michaud B, Combe C, Dantzer R, Parnet P. Role of
interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-
induced sickness behaviour: a study with interleukin-1 type I receptor-deficient
mice. Eur J Neurosci (2000) 12:4447–56. doi:10.1046/j.1460-9568.2000.01348.x
70. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants
on alternations in serum cytokines and depressive-like behavior in mice
after lipopolysaccharide administration. Pharmacol Biochem Behav (2013)
103:853–9. doi:10.1016/j.pbb.2012.12.003
71. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-
like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology
(2012) 62:419–26. doi:10.1016/j.neuropharm.2011.08.018
72. O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon
N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated
by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2009)
14:511–22. doi:10.1038/sj.mp.4002148
73. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, et al. Brain indoleamine
2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin
Invest (2012) 122:2940–54. doi:10.1172/JCI61884
74. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor
system and its role in physiological and pathological conditions. Clin Sci (Lond)
(2012) 122:143–59. doi:10.1042/CS20110340
75. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol
(2014) 26:237–45. doi:10.1016/j.smim.2014.02.009
76. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor func-
tion: relevance to glucocorticoid resistance and the pathophysiology and treat-
ment of major depression. Brain Behav Immun (2007) 21:9–19. doi:10.1016/j.
bbi.2006.08.009

























































Numakawa et al. BDNF dysfunction in comorbid depression
77. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, et al. The
proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid recep-
tor translocation and function. Endocrinology (1999) 140:4359–66. doi:10.
1210/en.140.9.4359
78. Wang X, Wu H, Miller AH. Interleukin 1alpha (IL-1alpha) induced activa-
tion of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor
function. Mol Psychiatry (2004) 9:65–75. doi:10.1038/sj.mp.4001339
79. Szatmáry Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-
mediated transcriptional activation by p38 mitogen-activated protein (MAP)
kinase. J Biol Chem (2004) 279:43708–15. doi:10.1074/jbc.M406568200
80. Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-
releasing factor-producing neurons in the rat activated by interleukin-1. Science
(1987) 238:524–6. doi:10.1126/science.2443979
81. Song C, Zhang Y, Dong Y. Acute and subacute IL-1β administrations differ-
entially modulate neuroimmune and neurotrophic systems: possible implica-
tions for neuroprotection and neurodegeneration. J Neuroinflammation (2013)
10:59. doi:10.1186/1742-2094-10-59
82. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1
beta impairs brain derived neurotrophic factor-induced signal transduction.
Neurobiol Aging (2008) 29:1380–93. doi:10.1016/j.neurobiolaging.2007.02.027
83. Tong L, Prieto GA, Kramár EA, Smith ED, Cribbs DH, Lynch G, et al. Brain-
derived neurotrophic factor-dependent synaptic plasticity is suppressed by
interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci (2012)
32:17714–24. doi:10.1523/JNEUROSCI.1253-12.2012
84. Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer
survival: a follow-up 10 years after diagnosis. Psychosom Med (2003) 65:636–43.
doi:10.1097/01.PSY.0000077503.96903.A6
85. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW, et al.
Depressive symptoms following interferon-α therapy: mediated by immune-
induced reductions in brain-derived neurotrophic factor? Int J Neuropsy-
chopharmacol (2011) 14:247–53. doi:10.1017/S1461145710000830
86. Hayley S, Scharf J, Anisman H. Central administration of murine interferon-α
induces depressive-like behavioral, brain cytokine and neurochemical alter-
ations in mice: a mini-review and original experiments. Brain Behav Immun
(2013) 31:115–27. doi:10.1016/j.bbi.2012.07.023
87. Anisman H, Poulter MO, Gandhi R, Merali Z, Hayley S. Interferon-alpha
effects are exaggerated when administered on a psychosocial stressor backdrop:
cytokine, corticosterone and brain monoamine variations. J Neuroimmunol
(2007) 186:45–53. doi:10.1016/j.jneuroim.2007.02.008
88. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, et al.
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.
J Clin Oncol (2008) 26:4820–7. doi:10.1200/JCO.2007.14.1978
89. Pyter LM, Pineros V, Galang JA, McClintock MK, Prendergast BJ. Peripheral
tumors induce depressive-like behaviors and cytokine production and alter
hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A (2009)
106:9069–74. doi:10.1073/pnas.0811949106
90. Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK.
Cancer induces inflammation and depressive-like behavior in the mouse: mod-
ulation by social housing. Brain Behav Immun (2011) 25:555–64. doi:10.1016/
j.bbi.2010.12.010
91. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol (2013) 75:225–40.
doi:10.1146/annurev-physiol-030212-183708
92. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants
via cytochrome P450 2D6. J Clin Psychiatry (2009) 70:1688–97. doi:10.4088/
JCP.08r04856blu
93. Carvalho AF, Hyphantis T, Sales PM, Soeiro-de-Souza MG, Macêdo DS, Cha
DS, et al. Major depressive disorder in breast cancer: a critical systematic review
of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev
(2014) 40:349–55. doi:10.1016/j.ctrv.2013.09.009
94. Patani N, Jiang WG, Mokbel K. Brain-derived neurotrophic factor expression
predicts adverse pathological & clinical outcomes in human breast cancer. Can-
cer Cell Int (2011) 11:23. doi:10.1186/1475-2867-11-23
95. Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, et al.
BDNF is associated with SFRP1 expression in luminal and basal-like breast
cancer cell lines and primary breast cancer tissues: a novel role in tumor sup-
pression? PLoS One (2014) 9:e102558. doi:10.1371/journal.pone.0102558
96. Martinac M, Pehar D, Karlovic D, Babic D, Marcinko D, Jakovljevic M.
Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and
inflammatory mediators in depressive disorder. Acta Clin Croat (2014)
53:55–71.
97. Noble EE, Billington CJ, Kotz CM, Wang C. The lighter side of BDNF. Am
J Physiol Regul Integr Comp Physiol (2011) 300:R1053–69. doi:10.1152/ajpregu.
00776.2010
98. Giles GE, Mahoney CR, Kanarek RB. Omega-3 fatty acids influence mood in
healthy and depressed individuals. Nutr Rev (2013) 71:727–41. doi:10.1111/
nure.12066
99. Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, et al.
Effect of diet on serotonergic neurotransmission in depression. Neurochem Int
(2013) 62:324–9. doi:10.1016/j.neuint.2012.12.014
100. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as
a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci
(2013) 14:401–16. doi:10.1038/nrn3505
101. Hong KW, Lim JE, Go MJ, Shin Cho Y, Ahn Y, Han BG, et al. Recapitulation
of the association of the Val66Met polymorphism of BDNF gene with BMI in
Koreans. Obesity (2012) 20:1871–5. doi:10.1038/oby.2011.352
102. Marqués-Iturria I, Garolera M, Pueyo R, Segura B, Hernan I, García-García
I, et al. The interaction effect between BDNF val66met polymorphism and
obesity on executive functions and frontal structure. Am J Med Genet B Neu-
ropsychiatr Genet (2014) 165B:245–53. doi:10.1002/ajmg.b.32229
103. Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, et al. Association study
of Val66Met polymorphism in brain-derived neurotrophic factor gene with
clozapine-induced metabolic syndrome: preliminary results. PLoS One (2013)
8:e72652. doi:10.1371/journal.pone.0072652
104. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. Conditional deletion
of brain-derived neurotrophic factor in the postnatal brain leads to obesity
and hyperactivity. Mol Endocrinol (2001) 15:1748–57. doi:10.1210/mend.15.
10.0706
105. Cordeira JW, Felsted JA, Teillon S, Daftary S, Panessiti M, Wirth J, et al.
Hypothalamic dysfunction of the thrombospondin receptor α2δ-1 under-
lies the overeating and obesity triggered by brain-derived neurotrophic fac-
tor deficiency. J Neurosci (2014) 34:554–65. doi:10.1523/JNEUROSCI.1572-
13.2014
106. Woo J, Shin KO, Park SY, Jang KS, Kang S. Effects of exercise and diet change on
cognition function and synaptic plasticity in high fat diet induced obese rats.
Lipids Health Dis (2013) 12:144. doi:10.1186/1476-511X-12-144
107. Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al.
Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell
Metab (2013) 18:649–59. doi:10.1016/j.cmet.2013.09.008
108. Wosiski-Kuhn M, Erion JR, Gomez-Sanchez EP, Gomez-Sanchez CE, Strana-
han AM. Glucocorticoid receptor activation impairs hippocampal plasticity by
suppressing BDNF expression in obese mice. Psychoneuroendocrinology (2014)
42:165–77. doi:10.1016/j.psyneuen.2014.01.020
109. Valladolid-Acebes I, Merino B, Principato A, Fole A, Barbas C, Lorenzo MP,
et al. High-fat diets induce changes in hippocampal glutamate metabolism
and neurotransmission. Am J Physiol Endocrinol Metab (2012) 302:E396–402.
doi:10.1152/ajpendo.00343.2011
110. Francis HM, Mirzaei M, Pardey MC, Haynes PA, Cornish JL. Proteomic analy-
sis of the dorsal and ventral hippocampus of rats maintained on a high fat and
refined sugar diet. Proteomics (2013) 13:3076–91. doi:10.1002/pmic.201300124
111. Wu A, Molteni R, Ying Z, Gomez-Pinilla F. A saturated-fat diet aggravates the
outcome of traumatic brain injury on hippocampal plasticity and cognitive
function by reducing brain-derived neurotrophic factor. Neuroscience (2003)
119:365–75. doi:10.1016/S0306-4522(03)00154-4
112. Kaczmarczyk MM, Machaj AS, Chiu GS, Lawson MA, Gainey SJ, York JM, et al.
Methylphenidate prevents high-fat diet (HFD)-induced learning/memory
impairment in juvenile mice. Psychoneuroendocrinology (2013) 38:1553–64.
doi:10.1016/j.psyneuen.2013.01.004
113. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, et al.
Impaired CNS leptin action is implicated in depression associated with obesity.
Endocrinology (2011) 152:2634–43. doi:10.1210/en.2011-0004
114. Jazvinšcak Jembrek M, Vukovic L, Puhovic J, Erhardt J, Oršolic N. Neuropro-
tective effect of quercetin against hydrogen peroxide-induced oxidative injury
in P19 neurons. J Mol Neurosci (2012) 47:286–99. doi:10.1007/s12031-012-
9737-1
115. Kim SS, Lim J, Bang Y, Gal J, Lee SU, Cho YC, et al. Licochalcone E acti-
vates Nrf2/antioxidant response element signaling pathway in both neuronal

























































Numakawa et al. BDNF dysfunction in comorbid depression
and microglial cells: therapeutic relevance to neurodegenerative disease. J Nutr
Biochem (2012) 23:1314–23. doi:10.1016/j.jnutbio.2011.07.012
116. Wang R, Tu J, Zhang Q, Zhang X, Zhu Y, Ma W, et al. Genistein attenuates
ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO-1 sig-
naling. Hippocampus (2013) 23:634–47. doi:10.1002/hipo.22126
117. Bhutada P, Mundhada Y, Bansod K, Ubgade A, Quazi M, Umathe S, et al.
Reversal by quercetin of corticotrophin releasing factor induced anxiety- and
depression-like effect in mice. Prog Neuropsychopharmacol Biol Psychiatry
(2010) 34:955–60. doi:10.1016/j.pnpbp.2010.04.025
118. Kawabata K, Kawai Y, Terao J. Suppressive effect of quercetin on acute stress-
induced hypothalamic-pituitary-adrenal axis response in Wistar rats. J Nutr
Biochem (2010) 21:374–80. doi:10.1016/j.jnutbio.2009.01.008
119. Jalsrai A, Numakawa T, Ooshima Y, Adachi N, Kunugi H. Phosphatase-
mediated intracellular signaling contributes to neuroprotection by flavonoids
of Iris tenuifolia. Am J Chin Med (2014) 42:119–30. doi:10.1142/
S0192415X14500086
120. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, et al. A selective TrkB
agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl
Acad Sci U S A (2010) 107:2687–92. doi:10.1073/pnas.0913572107
121. Chen J, Chua KW, Chua CC, Yu H, Pei A, Chua BH, et al. Antioxidant activity
of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced
toxicity. Neurosci Lett (2011) 499:181–5. doi:10.1016/j.neulet.2011.05.054
122. English AW, Liu K, Nicolini JM, Mulligan AM, Ye K. Small-molecule trkB ago-
nists promote axon regeneration in cut peripheral nerves. Proc Natl Acad Sci
U S A (2013) 110:16217–22. doi:10.1073/pnas.1303646110
123. Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, et al. Small-molecule
TrkB receptor agonists improve motor function and extend survival in a
mouse model of Huntington’s disease. Hum Mol Genet (2013) 22:2462–70.
doi:10.1093/hmg/ddt098
124. Swardfager W, Herrmann N, McIntyre RS, Mazereeuw G, Goldberger K,
Cha DS, et al. Potential roles of zinc in the pathophysiology and treat-
ment of major depressive disorder. Neurosci Biobehav Rev (2013) 37:911–29.
doi:10.1016/j.neubiorev.2013.03.018
125. Szewczyk B. Zinc homeostasis and neurodegenerative disorders. Front Aging
Neurosci (2013) 5:33. doi:10.3389/fnagi.2013.00033
126. Grønli O, Kvamme JM, Friborg O, Wynn R. Zinc deficiency is common in
several psychiatric disorders. PLoS One (2013) 8:e82793. doi:10.1371/journal.
pone.0082793
127. Huang L, Tepaamorndech S. The SLC30 family of zinc transporters – a review
of current understanding of their biological and pathophysiological roles. Mol
Aspects Med (2013) 34:548–60. doi:10.1016/j.mam.2012.05.008
128. Jeong J, Eide DJ. The SLC39 family of zinc transporters. Mol Aspects Med (2013)
34:612–9. doi:10.1016/j.mam.2012.05.011
129. Sindreu C, Palmiter RD, Storm DR. Zinc transporter ZnT-3 regulates presy-
naptic Erk1/2 signaling and hippocampus-dependent memory. Proc Natl Acad
Sci U S A (2011) 108:3366–70. doi:10.1073/pnas.1019166108
130. Sindreu C, Bayés Á, Altafaj X, Pérez-Clausell J. Zinc transporter-1 concentrates
at the postsynaptic density of hippocampal synapses. Mol Brain (2014) 7:16.
doi:10.1186/1756-6606-7-16
131. Chowanadisai W, Graham DM, Keen CL, Rucker RB, Messerli MA. Neurula-
tion and neurite extension require the zinc transporter ZIP12 (slc39a12). Proc
Natl Acad Sci U S A (2013) 110:9903–8. doi:10.1073/pnas.1222142110
132. Popovics P, Stewart AJ. GPR39: a Zn(2+)-activated G protein-coupled receptor
that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life
Sci (2011) 68:85–95. doi:10.1007/s00018-010-0517-1
133. Perez-Rosello T, Anderson CT, Schopfer FJ, Zhao Y, Gilad D, Salvatore SR, et al.
Synaptic Zn2+ inhibits neurotransmitter release by promoting endocannabi-
noid synthesis. J Neurosci (2013) 33:9259–72. doi:10.1523/JNEUROSCI.0237-
13.2013
134. Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of
TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron
(2008) 57:546–58. doi:10.1016/j.neuron.2007.11.026
135. Xu H, Gao HL, Zheng W, Xin N, Chi ZH, Bai SL, et al. Lactational zinc
deficiency-induced hippocampal neuronal apoptosis by a BDNF-independent
TrkB signaling pathway. Hippocampus (2011) 21:495–501. doi:10.1002/hipo.
20767
136. Tassabehji NM, Corniola RS, Alshingiti A, Levenson CW. Zinc deficiency
induces depression-like symptoms in adult rats. Physiol Behav (2008) 95:365–9.
doi:10.1016/j.physbeh.2008.06.017
137. Młyniec K, Budziszewska B, Reczynski W, Sowa-Kucma M, Nowak G. The role
of the GPR39 receptor in zinc deficient-animal model of depression. Behav
Brain Res (2013) 238:30–5. doi:10.1016/j.bbr.2012.10.020
138. Młyniec K, Doboszewska U, Szewczyk B, Sowa-Kucma M, Misztak P,
Piekoszewski W, et al. The involvement of the GPR39-Zn(2+)-sensing recep-
tor in the pathophysiology of depression. Studies in rodent models and sui-
cide victims. Neuropharmacology (2014) 79:290–7. doi:10.1016/j.neuropharm.
2013.12.001
139. Chen MD, Lin PY. Zinc-induced hyperleptinemia relates to the ameliora-
tion of sucrose-induced obesity with zinc repletion. Obes Res (2000) 8:525–9.
doi:10.1038/oby.2000.65
140. Panchal SK, Poudyal H, Brown L. Quercetin ameliorates cardiovascular,
hepatic, and metabolic changes in diet-induced metabolic syndrome in rats.
J Nutr (2012) 142:1026–32. doi:10.3945/jn.111.157263
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 30 June 2014; accepted: 12 September 2014; published online: 26 September
2014.
Citation: Numakawa T, Richards M, Nakajima S, Adachi N, Furuta M, Odaka H and
Kunugi H (2014) The role of brain-derived neurotrophic factor in comorbid depres-
sion: possible linkage with steroid hormones, cytokines, and nutrition. Front. Psychiatry
5:136. doi: 10.3389/fpsyt.2014.00136
This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in
Psychiatry.
Copyright © 2014 Numakawa, Richards, Nakajima, Adachi, Furuta, Odaka and
Kunugi. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Psychiatry | Molecular Psychiatry September 2014 | Volume 5 | Article 136 | 12
